0001104659-25-098082 Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 9th, 2025 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 6, 2025, between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 9th, 2025 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
This Agreement is made in connection with: (a) that certain Securities Purchase Agreement, dated as of the date hereof, among the Company and each Purchaser identified on the signature pages thereto, pursuant to which each such Purchasers will be issued securities of the Company in exchange for cash consideration pursuant to the terms thereof (the “Purchase Agreement”); and (b) that certain Lead Investor Agreement, dated on or about the date hereof, between the Company and the lead investor identified on the signature page thereto (the “Lead Investor”).
FORM OF WARRANT TO PURCHASE COMMON STOCKSecurity Agreement • October 9th, 2025 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
Leap Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [·] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [·] shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.5335 (the “Exercise Price”), in each case as adjusted from time to time as provided in Section 9, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the Original Issue Date and on or prior to 5:00 p.m. (New York City Time) on the tenth anniversary of the Original Issue Date (the “Terminat
LEAD INVESTOR AGREEMENTLead Investor Agreement • October 9th, 2025 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LEAD INVESTOR AGREEMENT (this “Agreement”) is made and entered into as of October 6, 2025 (the “Effective Date”) by and among Leap Therapeutics, Inc., a Delaware corporation (the “Company”) and Winklevoss Treasury Investments, LLC (the “Lead Investor”). The Company and the Lead Investor are collectively referred to herein as the “Parties” and each, a “Party”.
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEAP THERAPEUTICS, INC.Security Agreement • October 9th, 2025 • Leap Therapeutics, Inc. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Leap Therapeutics, Inc., a Delaware corporation (the “Company”), up to [●] shares of common stock, par value $0.001 per share (the “Common Stock” and such Common Stock underlying this Warrant, subject to adjustment hereunder, the “Warrant Shares”) of the Company. The purchase price of one share of Common Stock underlying this Warrant shall be equal to the Exercise Price set forth in Section 2(b) below.